US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
Content Sharing
<Market Commentary> HSI Fails to Hold 26,000; Alibaba, JD.com and Pharma Stocks Sought After
US President Donald Trump said the war with Iran has ended and there are no plans to extend the ceasefire agreement, with negotiations between the two sides possibly resuming in Pa...
Reset
Send
The window will close in 5 seconds
<Market Commentary> HSI Fails to Hold 26,000; Alibaba, JD.com and Pharma Stocks Sought After
Recommend
3
Positive
4
Negative
3
 
 

US President Donald Trump said the war with Iran has ended and there are no plans to extend the ceasefire agreement, with negotiations between the two sides possibly resuming in Pakistan within two days. The HSI opened higher today (15th) but pared gains later, failing to hold the 26,000 level. On hopes that the US and Iran may reach an agreement, the DJIA and Nasdaq rose 0.7% and 2% overnight (14th). At the time of writing, the US 2-year Treasury yield rose to 3.755%, while the US 10-year Treasury yield stood at 4.256%, and the US Dollar Index fell to 98.15. DJIA futures were last down 9 points or 0.02%, while Nasdaq futures rose 38 points or 0.15%. The Shanghai Composite Index edged up by less than 1 point to close at 4,027. The Shenzhen Component Index fell 1% and the ChiNext Index dropped 1.2%. Total turnover on the Shanghai and Shenzhen markets amounted to nearly RMB2.415 trillion.

The HSI opened 295 points higher and once climbed 344 points to a peak of 26,216. It closed up 75 points or 0.3% at 25,947, the days trough. The HSCEI rose 46 points or 0.5% to 8,718, while the HSTECH gained 59 points or 1.2% to 4,911. Total market turnover reached HKD245.588 billion. Southbound trading turnover totaled HKD106.462 billion, with net inflow of HKD4.221 billion today (net outflow of HKD2.017 billion in the previous trading day). Hong Kong Exchanges and Clearing (00388.HK)  +6.800 (+1.670%)    Short selling $271.84M; Ratio 12.414%   rose 1.7%. Yangtze Optical Fibre and Cable (06869.HK)  -10.800 (-4.991%)    Short selling $312.79M; Ratio 7.713%   slid nearly 5% to HKD205.6, with turnover of HKD4.11 billion. AI-related stocks Zhipu (02513.HK)  -81.000 (-8.544%)    Short selling $17.33M; Ratio 0.912%   and MiniMax (00100.HK)  -103.500 (-10.883%)    Short selling $274.76M; Ratio 14.695%   retreated 8.5% and 10.9%, while Unisound (09678.HK)  -41.800 (-11.176%)    Short selling $143.96K; Ratio 0.028%   dropped 11.2%.

CATL (03750.HK)  -4.500 (-0.682%)    Short selling $566.32M; Ratio 23.445%   fell 0.7% to HKD655.5. Tianqi Lithium (09696.HK)  -2.850 (-5.026%)    Short selling $16.85M; Ratio 4.403%   and Ganfeng Lithium (01772.HK)  -4.100 (-4.967%)    Short selling $128.12M; Ratio 14.410%   both declined nearly 5%.

Alibaba Supported; JD.com Sought After

Tech stocks broadly advanced. Baidu-SW (09888.HK)  +3.400 (+3.060%)    Short selling $239.19M; Ratio 22.882%   rose 3.1% to HKD114.5. Tencent (00700.HK)  +5.800 (+1.176%)    Short selling $1.01B; Ratio 10.936%   gained 1.2% to HKD499, while Meituan-W (03690.HK)  +1.200 (+1.410%)    Short selling $885.64M; Ratio 30.406%   and NetEase-S (09999.HK)  +2.400 (+1.369%)    Short selling $98.34M; Ratio 16.140%   each climbed 1.4%. Alibaba-W (09988.HK)  +4.100 (+3.293%)    Short selling $1.63B; Ratio 14.376%   rebounded nearly 3.3% to HKD128.6, with turnover of HKD12.319 billion. Alibaba Cloud announced that starting July 15 this year, it will adjust pricing for the Elasticity 95 feature under DDoS Native Protection 2.0 (annual/monthly subscription), DDoS High Defense (Mainland China), and DDoS High Defense (Non-Mainland China).

JD.com (09618.HK)  +5.300 (+4.593%)    Short selling $1.01B; Ratio 40.915%   jumped 4.6% to HKD120.7, with turnover of HKD2.839 billion. JPM released a research report reinstating an Overweight rating on JD.com with a TP of HKD148. The broker believes investors should focus on upside earnings risks for 2026 rather than the downside risks faced by many Chinese internet peers. It noted that the 4Q results last year and 2026 guidance demonstrated resilience in core operations, the most aggressive investment phase in instant retail has passed, and international expansion should be more prudent. JPM raised its 2026 and 2027 revenue forecasts by 1% and 2%, and lifted adjusted net profit forecasts by 13% and 26%, which are 17% and 7% above market consensus, respectively, mainly reflecting lower-than-expected losses in instant retail.

1,100 Stocks Advance; Pharma Shares Rally

Market breadth in Hong Kong slightly weakened. The ratio of advancers to decliners on the Main Board was 27 to 24 (32 to 19 in the previous session), with 1,141 stocks rising (up 3.07%). Among HSI constituents, 48 stocks rose while 40 fell, giving a ratio of 53 to 44 (68 to 32 in the previous session). Short selling amounted to HKD37.954 billion, accounting for 18.766% of the HKD202.254 billion turnover of securities eligible for short selling.

Mainland authorities issued guidelines to improve the drug pricing formation mechanism and optimize the pricing mechanism for innovative drugs and other first-launch products. Pharma stocks advanced. Sino Biopharmaceutical (01177.HK)  +0.340 (+5.832%)    Short selling $160.17M; Ratio 22.565%   , 3SBio (01530.HK)  +1.880 (+8.160%)    Short selling $211.64M; Ratio 12.341%   , Kelun-Biotech (06990.HK)  +33.800 (+6.966%)    Short selling $85.07M; Ratio 19.208%   , Innovent Biologics (01801.HK)  +5.100 (+5.910%)    Short selling $309.62M; Ratio 16.904%   , Akeso (09926.HK)  +9.500 (+6.889%)    Short selling $290.78M; Ratio 17.248%   and Junshi Biosciences (01877.HK)  +1.720 (+6.672%)    Short selling $39.61M; Ratio 17.685%   rose between 5.8% and 8.2%. Duality Biotherapeutics (09606.HK)  +31.000 (+10.809%)    Short selling $14.66M; Ratio 3.068%   and Rongchang Biotech (09995.HK)  +9.900 (+9.133%)    Short selling $55.05M; Ratio 6.890%   surged 10.8% and 9.1%, respectively.

Citi said the State Council of China issued the "Opinions on Reforming the Drug Pricing Formation Mechanism", describing it as a landmark national guidance document that continues a series of innovation-encouraging policies. The broker considers it the most significant central government drug pricing guidance since 2015. The policy aims to allow the market to play a leading role in drug pricing. Citi views this as a clear commitment by the government to foster a strong and globally competitive domestic pharmaceutical industry. It believes major innovative pharmaceutical and biotech companies will benefit, including Hengrui Pharmaceuticals (01276.HK)  +2.650 (+4.037%)    Short selling $14.14M; Ratio 4.904%   , CSPC Pharmaceutical (01093.HK)  +0.280 (+3.057%)    Short selling $176.83M; Ratio 24.483%   , Innovent Biologics and other multinational companies with substantial innovative drug sales in China. (wl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-15 16:25.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI

AASTOCKS Financial News

Related Stocks
0/0
 
SITEMAP
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

As a convenience to users, the AASTOCKS.com Limited has added a translation feature developed by Azure OpenAI to assist users in understanding information on this platform in languages other than Chinese. The translated text may lose some of its intended meaning. Some items on the site, including images containing text, videos with captioning, PDF documents, or maps may not be translated, and some features may not work in the translated versions.

The AASTOCKS.com Limited does not guarantee the accuracy of translations, and the translated text should not be considered exact. The text translated is made available on an as is and as available basis without any warranties of any kind. The AASTOCKS.com Limited will not accept any liability for damages or losses of any kind caused by the use of the translation feature.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 9 February 2026.